



**Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes  
a cohort profile**

Christensen, Diana Hedevang; Nicolaisen, Sia Kromann; Berencsi, Klára; Beck-Nielsen, Henning; Rungby, Jørgen; Friborg, Søren; Brandslund, Ivan; Christiansen, Jens Sandahl; Vaag, Allan; Sørensen, Henrik Toft; Nielsen, Jens Steen; Thomsen, Reimar Wernich

*Published in:*  
BMJ Open

*DOI:*  
[10.1136/bmjopen-2017-017273](https://doi.org/10.1136/bmjopen-2017-017273)

*Publication date:*  
2018

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY-NC](#)

*Citation for published version (APA):*  
Christensen, D. H., Nicolaisen, S. K., Berencsi, K., Beck-Nielsen, H., Rungby, J., Friborg, S., Brandslund, I., Christiansen, J. S., Vaag, A., Sørensen, H. T., Nielsen, J. S., & Thomsen, R. W. (2018). Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. *BMJ Open*, 8(4), 1-11. [e017273]. <https://doi.org/10.1136/bmjopen-2017-017273>

# BMJ Open Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile

Diana Hedevang Christensen,<sup>1</sup> Sia Kromann Nicolaisen,<sup>1</sup> Klára Berencsi,<sup>1</sup> Henning Beck-Nielsen,<sup>2</sup> Jørgen Rungby,<sup>3,4</sup> Søren Friberg,<sup>5</sup> Ivan Brandslund,<sup>6</sup> Jens Sandahl Christiansen,<sup>7</sup> Allan Vaag,<sup>8</sup> Henrik Toft Sørensen,<sup>1,9</sup> Jens Steen Nielsen,<sup>2</sup> Reimar Wernich Thomsen<sup>1</sup>

**To cite:** Christensen DH, Nicolaisen SK, Berencsi K, *et al.* Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. *BMJ Open* 2018;**8**:e017273. doi:10.1136/bmjopen-2017-017273

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-017273>).

Dr Jens Sandahl Christiansen died on 16 December 2015.

Received 20 April 2017  
Revised 12 February 2018  
Accepted 2 March 2018



For numbered affiliations see end of article.

## Correspondence to

Dr Reimar Wernich Thomsen;  
[rwt@clin.au.dk](mailto:rwt@clin.au.dk)

## ABSTRACT

**Purpose** The aim of this article is to provide a detailed description of the ongoing nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort and biobank. The DD2 cohort continuously enrolls newly diagnosed patients with type 2 diabetes (T2D) throughout Denmark. The overall goal of the DD2 project is to establish a large and data-rich T2D cohort that can serve as a platform for exhaustive T2D research including (1) improved genotypic and phenotypic characterisation of T2D, (2) intervention studies of more individualised T2D treatment, (3) pharmacoepidemiological studies and (4) long-term follow-up studies on predictors of T2D complications and prognosis.

**Participants** Between 2010 and 2016, 7011 individuals with T2D have been enrolled and assessed at baseline. Information collected include interview data (eg, body weight at age 20 years, physical activity and alcohol consumption), clinical examination data (eg, hip–waist ratio and resting heart rate) and biological samples (whole blood, DNA, plasma and urine) stored at –80°C and currently analysed for a range of biomarkers and genotypes.

**Findings to date** Registry linkage has provided extensive supplemental continuous data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, cancer and mortality. Cross-sectional associations between biomarkers, family history, anthropometric and lifestyle measures and presence of complications at baseline have been reported.

**Future plans** During 2016, a detailed follow-up questionnaire has been answered by 85% of initial participants, providing follow-up information on baseline variables and on presence of diabetic neuropathy. The DD2 cohort has now been followed for a total of 18 862 person-years, and nested intervention trials and follow-up studies are ongoing. In the future, the cohort will serve as a strong national and international resource for recruiting patients to nested case studies, clinical trials, postmarketing surveillance, large-scale genome studies and follow-up studies of T2D complications.

## Strengths and limitations of this study

- The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort is an ongoing Danish cohort and biobank of newly diagnosed patients with type 2 diabetes (T2D) continuously enrolled on a nationwide level since 2010.
- By 2016, 7011 patients have been recruited from general practitioners (53%) and hospital specialist outpatient clinics (47%).
- The cohort includes baseline interview data, physical examination data, biological samples (DNA, blood and urine) as well as baseline and follow-up data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, incident cancers, mortality and causes of death.
- The cohort may represent patients with more advanced T2D than average, and 85% already had initiated glucose-lowering treatment at enrolment that hampers studies of drug-naïve patients with T2D.
- In the future, the DD2 cohort will serve as a strong national and international resource for recruiting patients to nested clinical trials, large-scale genome studies and long-term follow-up studies of T2D complications through linkage with the large network of existing population-based registries in Denmark.

## INTRODUCTION

Type 2 diabetes (T2D) is associated with a wide range of devastating complications, classically including cardiovascular disease, end-stage renal disease, blindness, diabetic foot ulcers and amputations. T2D also increases risk of infections, some cancers and neuropsychiatric disease.<sup>1</sup> These complications inflict a burden on the healthcare system as well as on the individual patients with diabetes. Since it is hard to prevent T2D, there is a compelling

need for cost-effective research to target and improve diabetes treatment in order to prevent complications. Fortunately, over the last decades, the number of available glucose-lowering treatment options has increased,<sup>2</sup> facilitating individually tailored treatment. In this context determining how genotype and phenotype may influence the optimal choice of treatment is essential.<sup>3</sup>

Denmark has a tax-supported healthcare system that includes free access to care at general practitioners (GPs) and hospitals as well as partial reimbursement for most prescribed drugs, including diabetes drugs.<sup>4</sup> GPs—the gatekeepers of the Danish National Health Service—are responsible for nearly all referrals to hospitals and specialists. Patient contacts with health and social services are extensively documented at the individual level in national databases using the unique civil personal registration number (CPR number) that has been assigned since 1968 to all Danish residents at birth or on immigration.<sup>4</sup>

In this setting, the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project was established in 2010. The Project's overall goal is to provide an international resource for T2D research. It encompasses establishment of the nationwide and data-rich DD2 cohort and a linked biobank of DNA, blood and urine. The study rationale has been to provide a platform for improved genotypic and clinical characterisation of T2D, for developing more individualised treatment and for testing new antidiabetic drugs in nested intervention studies. Moreover, to establish a unique T2D patient cohort by linkage with the large network of existing population-based registries in Denmark, through which patients can be followed longitudinally for a variety of clinical and socioeconomic outcomes for decades, allowing improved understanding of the predictors of long-term diabetes prognosis.

The aim of this cohort profile paper is to provide a description of the DD2 cohort as an international T2D research resource, including an overview of the collected data and a description of the baseline characteristics.

## COHORT DESCRIPTION

### Study participants and recruitment

Since 1 January 2009, all patients with newly or recently diagnosed T2D in Denmark have been eligible to participate in the DD2 cohort. The first patient was enrolled in November 2010, and the cohort now consists of 7011 patients. The DD2 project is ongoing, with continuous enrolment.

The process of enrolling in the DD2 cohort has been described in detail elsewhere<sup>5</sup>: (1) clinical providers (usually either the patient's GP or a hospital physician/nurse) identify patients newly diagnosed with T2D in routine clinical practice. (2) Those patients are informed by the clinical provider about the existence of the DD2 project. (3) Patients interested in participating receive detailed oral and written information and are asked to sign a written informed consent document for enrolment. (4) Patient clinical information is then collected: GPs or

hospital physicians/nurses complete an online questionnaire, including items requiring a physical examination. (5) Urine and fasting blood samples are collected for storage in a biobank.<sup>6</sup>

Approximately 80% of patients with T2D in Denmark receive care at GPs' offices and the remainder at hospital specialist outpatient clinics. Enrolment into the DD2 cohort takes place in both settings (figure 1). From 2010 to 2012, most patients were enrolled at hospital outpatient clinics rather than at GP offices (1559 vs 739 patients). From 2013 on, the number of patients recruited by GPs increased rapidly,<sup>7</sup> reaching 3688 in February 2016. As of that month, the corresponding number of patients recruited by outpatient specialist clinics was 3323 (table 1).


During the entire DD2 enrolment period, all diagnosing of T2D in routine clinical practice has been made according to WHO criteria, before 2012 primarily based on OGTT and after 2012 primarily based on glycosylated haemoglobin A (HbA1c) >48 mmol/mol (6.5%). No further diagnostic criteria for enrolment have been applied in the DD2 project. The DD2 project explicitly aims to comprehensively study T2D as diagnosed in everyday clinical care, as one of the project aims is to document pitfalls in initial T2D diagnosing, including investigation of subtypes and subphenotypes in the cohort, occurrence of secondary diabetes, autoimmune diabetes and so on.

While the DD2 cohort from the beginning aimed to focus on newly diagnosed T2D patients, in clinical practice, the referral to DD2 may not happen at first diabetes notice when other clinical activity may be more pertinent. Individuals who have had prevalent T2D for some time after 2009 are also accepted for participation. While we do not have complete data on exact date of diabetes diagnosis for all individuals, average time from first recorded glucose-lowering drug initiation to enrolment date in the DD2 cohort is 1–1.5 years.

The exact proportion of all patients with incident T2D in Denmark that is enrolled into the DD2 cohort is unknown. With an average enrolment in the order of 1000–1200 DD2 patients per year, the project enrolls an estimated 5% of newly diagnosed patients with T2D nationwide.

The number of enrolled patients and recruitment sites vary across the five Danish healthcare regions. Currently, the largest proportion (35%) of the cohort patients has been recruited from the region of Southern Denmark, which comprises 21% of Denmark's population, followed by the Central Denmark Region (with 24% of cohort patients) and the Capital Region (with 19% of cohort patients), comprising 22% and 31% of Denmark's population, respectively.

Loss of patients from the DD2 cohort can occur due to emigration and death. These events are identified by linkage to the Danish Civil Registration System (CRS), which has recorded vital status for the entire Danish population since 1968, with daily electronic updates.<sup>4</sup> Enrolled



**Figure 1** Enrolment sites throughout Denmark. Every circle represents an enrolment site, either at a general practitioner's office or at an outpatient clinic. The administrative headquarter of the DD2 is in Odense (red dot). DD2, Danish Centre for Strategic Research in Type 2 Diabetes.

patients have the right to withdraw from the DD2 cohort, but only four individuals have done so thus far.

### Data collection

Baseline data recorded in the DD2 database include each patient's CPR number, date of enrolment and DD2 variables collected directly at the enrolment visit (interview data, clinical examination data and biobank data). Furthermore, linkage with a wide range of Danish health and administrative registries, including the Danish Diabetes Database for Adults (DDDA), one of several Danish nationwide public clinical quality improvement

registries,<sup>7</sup> ensures important additional baseline data (figure 2).

The cohort is followed prospectively through linkage with the DDDA and other Danish administrative and health registries. Moreover, directly collected data are used to follow DD2 patients for outcomes not routinely available in medical registries as described below.

### Directly collected DD2 baseline variables


These include waist-hip ratio, recalled body weight at age 20 years, maximum lifetime body weight, alcohol consumption, family history of diabetes, resting heart

**Table 1** Geographical distribution of DD2 participants by recruitment setting and year of enrolment

Region	Hospital outpatient clinics, N								General practitioners' offices, N						
	2010	2011	2012	2013	2014	2015	2016	Total	2011	2012	2013	2014	2015	2016	Total
Capital	0	23	246	197	199	85	5	755	7	144	259	134	39	5	588
Central Denmark	18	211	356	299	222	195	7	1308	0	38	192	84	72	5	391
North Denmark	0	2	52	16	73	19	5	167	0	31	276	161	30	0	498
Zealand	0	0	0	6	20	4	0	30	3	1	432	239	71	11	757
Southern Denmark	0	334	303	168	160	93	5	1063	184	324	237	147	471	50	1413
Unspecified	–	–	–	–	–	–	–	–	–	2	29	7	1	2	41
<b>Total Denmark</b>	<b>18</b>	<b>570</b>	<b>957</b>	<b>686</b>	<b>674</b>	<b>396</b>	<b>22</b>	<b>3323</b>	<b>194</b>	<b>540</b>	<b>1425</b>	<b>772</b>	<b>684</b>	<b>73</b>	<b>3688</b>

DD2, Danish Centre for Strategic Research in Type 2 Diabetes.





**Figure 2** Flow chart of data collection in the DD2 cohort study. DD2, Danish Centre for Strategic Research in Type 2 Diabetes; DDDA, Danish Diabetes Database for Adults; HbA1c, glycosylated haemoglobin A; SF-12, 12-Item Short Form Health Survey.

rate, physical activity level and (added in 2015) self-reported date of first T2D diagnosis. The self-reported physical activity level is currently being validated by placing accelerometers (AX3, Axivity, Newcastle, UK) directly on the skin of the thigh and back of persons in a subcohort of DD2 participants ( $n=1000$ ), and all physical activity is recorded over a 10-day period. Moreover, a smartphone application ([www.interwalk.dk](http://www.interwalk.dk)) holding an interval-based training program has been developed. DD2 participants are encouraged to download and use this application, which guides and monitors their physical exercise. The logged exercise data are then transferred to the DD2 cohort and allow future investigations of for example, the impact of exercise on risk of T2D complications. Urine and blood samples (whole blood, serum, plasma and purified DNA) are stored in a biobank<sup>6</sup> and can be used for myriad purposes. To date, plasma samples have been analysed for a number of baseline variables, including fasting blood glucose, C-peptide (used in homeostatic model assessment of insulin resistance), glutamic acid decarboxylase antibodies, alanine-aminotransferases (ALAT), amylase and C reactive protein (CRP). Several currently initiated and planned studies will provide a larger range of analysed biobank variables. For instance, DNA has been purified from 6000 patients and 'maturity-onset diabetes of the young' (MODY) genes are now being sequenced in order to identify individuals carrying likely pathogenic variants. As well, studies of


the prevalence of 'latent autoimmune diabetes in adults' in cohort members and the impact of the inflammatory system on diabetic complications have been initiated and will lead to analyses of additional biomarkers, including mannan-binding lectin.

#### Variables provided by the DDDA

The DDDA, established in 2005, provides a key source of supplemental individual-level data.<sup>7</sup> Quality of care data (variables outlined below) are submitted from GP offices and outpatient clinics to the DDDA annually or biennially. The DDDA thus can provide baseline and follow-up data for members of the DD2 cohort including data on the T2D diagnosis date first recorded in the healthcare system, tobacco smoking, completion of examinations for diabetic foot and eye disease, body mass index (BMI), physician-reported antidiabetic treatment, antihypertensive treatment, hypolipidaemic treatment and routine laboratory measurements such as HbA1c, plasma lipids and albuminuria.

#### Administrative and health registries

Migration and civil status can be ascertained from the CRS<sup>4</sup> (figure 3). The Danish National Patient Registry (DNPR)<sup>8</sup> maintains complete data on all hospital admissions since 1977 and on all hospital outpatient clinic and emergency room contacts since 1995, including dates of admission and discharge, visit dates, surgical procedures



**Figure 3** Schematic overview of individual-level data linkage in the DD2 cohort using the civil registration number as personal identification. DD2, Danish Centre for Strategic Research in Type 2 Diabetes.

performed and primary and secondary discharge diagnoses coded according to the *International Classification of Diseases*, 8th Revision until the end of 1993 and 10th Revision thereafter. Linkage to the DNPR makes it possible to obtain individual-level information at baseline and during follow-up on diseases and treatments relevant to diabetes, such as cardiovascular events, microvascular complications and dialysis. On the basis of diagnoses in the DNPR, the baseline comorbidity burden of each DD2 participant is calculated using Charlson Comorbidity Index (CCI) scores<sup>9</sup> (low: 0 points, medium: 1–2 points, high  $\geq 3$  points; diabetes is excluded as it constitutes the index disease). Linkage to the Danish National Health Service Prescription Database (DNHSP)<sup>10</sup> provides individual-level information on reimbursable drugs dispensed at all pharmacies in Denmark allowing to track treatment history of each DD2 participant. Pharmacy data include the date of dispensing, as well as amount and type of drug prescribed according to the Anatomical Therapeutic Chemical classification system. The Danish Cancer Registry (DCR)<sup>11</sup> has recorded data on cancer diagnoses in Denmark since 1943 and is a valuable resource for studying cancer in patients with T2D. Linkage to the Danish Register of Causes of Death (DRCD)<sup>12</sup> allows evaluation of cause-specific mortality, while linkage to the Statistics Denmark database provides socioeconomic data, for example, on education, job level and income. The National Health Insurance Service Registry contains information on all services provided by GPs and specialists in Denmark since 1990, including physiotherapists, dentists and chiropractors. Data on services include the number of contacts, health service provider and type of service (eg, consultation, blood glucose measurement or vaccination).<sup>13</sup>

### Questionnaire data 2016

By June 2016, all enrolled DD2 patients were sent questionnaires to gather follow-up data (described below) as well as data on the prevalence of diabetic neuropathy. Neuropathy-related questions included, among others, the Michigan Neuropathy Screening Instrument questionnaire, the Douleur Neuropathique 4 questionnaire and other pain-related questions. A random sample of patients reporting symptoms of painful and non-painful neuropathy as well as a random sample of control patients without symptoms will be invited for an in-depth neuropathy examination during 2016–2018, which will allow comprehensive investigation of this late diabetic complication. The questionnaires also maintained follow-up questions regarding the lifestyle factors included in the baseline study interview, including alcohol use, smoking habits and physical activity (figure 2). Preliminary data from this questionnaire survey have revealed a remarkable response rate of 85%.

Also, quality of life 12-Item Short Form Health Survey (SF-12) questionnaires have recently been emailed to all DD2 cohort members with a known email address (n=2629). As of August 2016, 1002 patients (38% of those with email addresses) had responded to this questionnaire. Follow-up SF-12 questionnaires will be emailed automatically every second year.

### Baseline characteristics of study participants

An overview of the interview and clinical examination data collected from the 7011 patients enrolled in the DD2 between November 2010 and February 2016 is provided in table 2.

As of February 2016, the DD2 cohort consisted of 4065 (58%) men, the median age was 61 years (IQR:

**Table 2** Characteristics of patients with newly diagnosed type 2 diabetes enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project during November 2010–February 2016

Variables	Patients with type 2 diabetes
<b>Persons enrolled in DD2 by February, 2016, n (%)</b>	7011 (100)
Enrolled from general practitioners' offices, n (%)	3688 (53)
Enrolled from hospital clinics, n (%)	3323 (47)
Median age (IQR), years	61 (52–68)
Minimum–maximum age, years	17–95
Gender, n (%)	
Male	4065 (58)
Female	2946 (42)
Resting heart rate, median (IQR)	70 (63–79)
Waist circumference, median (IQR), cm	106 (97–116)
Waist–hip ratio in men, median (IQR)	1.02 (0.97–1.06)
Waist–hip ratio in women, median (IQR)	0.92 (0.87–0.97)
Median weight at 20 years of age (IQR), kg	70 (60–80)
Weight unknown at age 20, n (%)	929 (13)
Median maximum lifetime weight (IQR), kg	100 (86–115)
Maximum lifetime weight unknown, n (%)	75 (1)
Alcohol use, n (%)	
Maximum 14/21 drinks/week (women/men)	6539 (93)
More than 14/21 drinks/week (women/men)	472 (7)
Days per week with 30+ min of physical activity (days)	
0	1161 (17)
1	488 (7)
2	891 (13)
3	954 (14)
4	622 (9)
5	681 (10)
6	317 (5)
7	1897 (27)
Regular sports activities, n (%)	
Yes	2748 (39)
No	4262 (61)
Level of physical activity during the past year, n (%)	
Hard physical training and competitive sports several times a week	55 (1)
Leisure sports, heavy garden work or similar activity at least 4 hours per week	1370 (20)

Continued

**Table 2** Continued

Variables	Patients with type 2 diabetes
Walking, cycling or other light exercise at least 4 hours per week	4298 (61)
Reading, television watching or other sedentary activity	1288 (18)
Family history of diabetes, n (%)	
Yes	3717 (53)
No	2696 (39)
Don't know	598 (9)
Median fasting blood glucose (IQR), mmol/L*	7.1 (6.4–8.3)
Median C-peptide†‡ (IQR), pmol/L	1161 (865–1570)
Glutamic acid decarboxylase antibodies§	
≤30 kU/L, N (%)	5655 (97)
>30 kU/L, N (%)	161 (3)
Median alanine-aminotransferases¶ (IQR), U/L	27 (20–38)
Median pancreatic amylase¶ (IQR), U/L	23 (16–30)
Median C reactive protein¶ (IQR), mg/L	2.1 (1.0–4.8)

\*Currently analysed for the first consecutive 5363 DD2 patients.

†Reference range: 400–1600 pmol/L.

‡Currently analysed for the first consecutive 5800 DD2 patients.

§Currently analysed for the first consecutive 5816 DD2 patients.

¶Currently analysed for the first consecutive 1018 DD2 patients.

52–68 years) and 3717 (53%) patients had a known family history of diabetes. In regard to exercise, 1161 patients (17%) reported less than 30 min and 1897 patients (27%) reported at least 30 min of physical activity 7 days per week. Overall, 2748 patients (39%) reported regular sports activities. At baseline, 7% (n=472) consumed more alcohol per week than the recommended maximum safe amount in Denmark (maximum of 14/21 drinks per week for women/men). Weight at 20 years of age was available for 6082 study participants, with a median value of 70 kg (IQR: 60–80 kg). The median value of maximum lifetime weight was 100 kg (IQR: 86–115 kg) in the cohort. Median waist–hip ratios were 1.02 (IQR: 0.97–1.06) in men and 0.92 (IQR: 0.87–0.97) in women. To date, biological samples have been obtained from more than 93% of cohort members, with a median fasting blood glucose measurement of 7.1 mmol/L (minimum–maximum: 2.5–29 mmol/L) and a median C-peptide measurement of 1161 pmol/L (IQR: 865–1570 pmol/L).<sup>14</sup>

By September 2015, 5115 patients (73%) had been linked to the DDDA quality-of-care database (table 3).

Of the 3835 patients with a known BMI value, 37% of men were overweight at DD2 enrolment and 52% were obese, while 29% of women were overweight and 55% were obese. Seventeen per cent (n=886) were

**Table 3** Characteristics of 5115 patients enrolled in the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project, which currently can be linked to the Danish Diabetes Database for Adults

Variables	Patients with type 2 diabetes
<b>N (%) of DD2 participants who could be linked to the Danish Diabetes Database for Adults, as of September 2015.</b>	5115 (73)
Tobacco smoking, n (%)	
Never smoker	2254 (44)
Former smoker	1649 (32)
Current smoker, daily	886 (17)
Current smoker, occasionally	55 (1)
Smoking status listed as unknown	271 (5)
<b>Men (n=2984)</b>	
Median height (IQR), cm	178 (174–183)
Height missing, n (%)	709 (24)
Current median weight (IQR), kg	96 (85–110)
Weight missing, n (%)	229 (8)
Current BMI, n (% of those with known BMI)	
<18.5	2 (0)
18.5–24.9	250 (11)
25–29.9	833 (37)
30+	1183 (52)
BMI missing	716
<b>Women (n=2131)</b>	
Median height (IQR), cm	164 (160–169)
Height missing, n (%)	561 (26)
Current median weight (IQR), kg	84 (71–96)
Weight missing, n (%)	188 (4)
Current BMI, n (% of those with known BMI)	
<18.5	8 (1)
18.5–24.9	240 (15)
25–29.9	458 (29)
30+	861 (55)
BMI missing	564
HbA1c value	
<7%	3592 (70)
7.0%–8.0%	824 (16)
8.0%–9.0%	303 (6)
≥9.0%	313 (6)
HbA1c missing	83 (2)
Albuminuria, N (%)	
Albumin–creatinine ratio <30 mg/g	3565 (70)
Albumin–creatinine ratio 30–300 mg/g	830 (16)
Albumin–creatinine ratio ≥300 mg/g	110 (2)

Continued

**Table 3** Continued

Variables	Patients with type 2 diabetes
Albuminuria–creatinine ratio missing	610 (12)
Blood pressure, median (IQR), mm Hg	
Systolic	130 (124–140)
Diastolic	80 (74–85)
Lipids, median (IQR), mmol/L	
Total cholesterol	4.4 (3.7–5.1)
HDL cholesterol	1.2 (1.0–1.5)
LDL cholesterol	2.2 (1.7–2.8)
Triglycerides	1.6 (1.2–2.4)
Physician-reported antidiabetic treatment, n (%)*	
Insulin only	59 (1)
Insulin and oral antidiabetic treatment	306 (6)
Oral antidiabetic treatment	3993 (78)
None	757 (15)
Physician-reported antihypertensive treatment, n (%)	3523 (69)
Physician-reported ACE inhibitor or ATII-antagonist treatment, n (%)	2786 (54)
Physician-reported hypolipidaemic treatment	3373 (66)
Eye screening completed	2762 (54)
Foot examination completed	4362 (85)

\*Within the year prior to enrolment in the DD2 cohort. ATII-antagonist, angiotensin 2 antagonist; BMI, body mass index; HbA1c, glycosylated haemoglobin A; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

current daily smokers, and 32% (n=1649) were former smokers. Most had an HbA1c value below 7.0% (70%) and 4358 (85%) had received antidiabetic treatment within the year prior to enrolment; 59 patients (1%) were taking only insulin and 3993 (78%) received only oral antidiabetic treatment, as confirmed by routine prescription data from DNHSP. A diabetic eye examination had been performed on 2762 (54%) cohort members and a foot examination on 4362 (85%). At DD2 enrolment, microalbuminuria was present in 16% of patients, and macroalbuminuria was present in 2%. Median systolic/diastolic blood pressure was 130/80, and 3523 patients (69%) were being treated for hypertension. Median total cholesterol was 4.4 (IQR: 3.7–5.1) mmol/L; 3373 patients (66%) were receiving hypolipidaemic treatment. Linkage of the DD2 cohort to the DNPR and DNHSP revealed that approximately one-third of patients had hospital-diagnosed comorbidity (CCI score ≥1 point) prior to enrolment. Twenty-two per cent had hospital-diagnosed macrovascular disease, and 15% had microvascular complications prior to enrolment (table 4).



**Table 4** Comorbidities (determined through linkage with the DNPR) and use of medications (determined through linkage with the DNHSP) at enrolment among the first 7011\* patients with newly diagnosed type 2 diabetes enrolled in the DD2 project

Variables	Patients with type 2 diabetes
<b>Persons enrolled in DD2 by February 2016, n (%)</b>	7011 (100)
Charlson Comorbidity Index score†	
0	4807 (69)
1–2	1820 (26)
3+	384 (5)
Charlson Comorbidity Index conditions at baseline, n (%)	
Myocardial infarction	345 (5)
Congestive heart failure	283 (4)
Peripheral vascular disease	309 (4)
Cerebrovascular disease	465 (7)
Dementia	13 (0.2)
Chronic pulmonary disease	510 (7)
Connective tissue disease	183 (3)
Ulcer disease	126 (2)
Mild liver disease	111 (2)
Hemiplegia	19 (0.3)
Moderate to severe renal disease	117 (2)
Any tumour	508 (7)
Leukaemia	15 (0.2)
Lymphoma	26 (0.4)
Moderate to severe liver disease	16 (0.2)
Metastatic solid tumour	43 (0.6)
HIV/AIDS	9 (0.1)
Any macrovascular complications	1511 (22)
Any microvascular complications	1035 (15)
Diabetic neuropathy	230 (3)
Diabetic retinopathy	682 (10)
Diabetic nephropathy	209 (3)
Mental disorder (based on discharge and treatment codes for mental illness)*	1456 (21)
Antidiabetic treatment, n (%)‡	
Insulin only	80 (1)
Insulin and oral antidiabetic treatment	396 (6)
Oral antidiabetic treatment	5387 (78)
None	1053 (15)
Glucose-lowering drugs, n (%)‡	
Biguanides (metformin)	5631 (81)
Insulin	476 (7)
Sulfonylureas	463 (7)
DPP-4 inhibitors	653 (9)
GLP-1 analogues	378 (5)
SGLT-2 inhibitors	57 (0.8)

Continued

**Table 4** Continued

Variables	Patients with type 2 diabetes
Meglitinides	7 (0.1)
Thiazolidinediones (glitazones)	1 (0.01)
Alpha-glucosidase inhibitors	4 (0.06)
Antihypertensive treatment excluding loopdiuretics, n (%)‡	4991 (72)
ACE inhibitors or ATII-antagonist treatment, n (%)‡	4157 (60)
Hypolipidaemic treatment, n (%)‡	4886 (71)
Oral steroids, n (%)‡	430 (6)

\*At the time of analysis, full prescription data were available only until 31 December 2015. Therefore, variables based on data from the DNHSP are for a subcohort numbering 6916 patients.  
†Diabetes mellitus not included in the score as it constitutes the index disease. Comorbidity categories include DNPR derived data on cancer; more detailed cancer data are available from the Danish Cancer Registry.  
‡Within the last year prior to DD2 enrolment.  
ATII-antagonist, angiotensin 2 antagonist; DD2, Danish Centre for Strategic Research in Type 2 Diabetes; DNPR, Danish National Patient Registry; DNHSP, Danish National Health Service Prescription; DPP-4-inhibitors, dipeptidylpeptidase 4 inhibitors; GLP-1 analogues, glucagon-like peptide 1 analogues; SGLT-2 inhibitors, sodium glucose cotransporter 2 inhibitors.

## FINDINGS TO DATE

### Mortality ratios

The DD2 cohort has been followed for a total of 18862 person-years (PY) and a mean of 2.7 years. A total of 212 patients have died, yielding an all-cause mortality rate (MR) of 1.12 per 100 PY (95% CI 0.97 to 1.29), with differences by gender (MR for women: 0.81 (95% CI 0.62 to 1.03); MR for men: 1.36 (95% CI 1.15 to 1.60)). As expected, all-cause MR increased with age (table 5).

**Table 5** Number of deaths and overall, age-specific and gender-specific mortality rates (per 100 person-years) for the baseline cohort of 7011 DD2 patients

Variables	Number of deaths	MR (95% CI)
Total DD2 cohort	212	1.12 (0.97 to 1.29)
Gender		
Women	65	0.81 (0.62 to 1.03)
Men	147	1.36 (1.15 to 1.60)
Age (years)		
<40	2	0.23 (0.03 to 0.83)
40–59	37	0.50 (0.35 to 0.69)
60–79	149	1.47 (1.25 to 1.73)
≥80	24	4.97 (3.19 to 7.40)

Median follow-up time from date of enrolment to death or to date of latest data extraction from the Civil Registration System was 2.68 years (IQR: 1.67–3.63 years).  
DD2, Danish Centre for Strategic Research in Type 2 Diabetes; MR, mortality rate.

## Key findings

Several baseline cross-sectional studies based on preliminary findings for parts of the current DD2 cohort were published in 2014–2016.<sup>15–20</sup> Parental history of T2D was associated with younger age at diagnosis (adjusted prevalence ratio (aPR) for age <40 years: 1.66 (95% CI 1.19 to 2.31); aPR for age 40–60 years: 1.36 (95% CI 1.24 to 1.48)), as well as poorer glucose control at diagnosis (aPR for fasting blood glucose <6.5 mmol/L: 0.80 (95% CI 0.62 to 1.02) and aPR for fasting blood glucose ≥7.5 mmol/L: 1.47 (95% CI 1.20 to 1.80)). No associations were observed for anthropometric and lifestyle factors, while parental history tended to be negatively associated with the high beta cell function phenotype<sup>18</sup> (aPR 0.79 (95% CI 0.61 to 1.01)). This suggests that patients with T2D may not inherit diabetes primarily as a result of family-learned lifestyle habits (physical inactivity and overeating), but rather as a result of a constitutional impairment of insulin action/secretion.<sup>18</sup> In studies of DD2 biobank data, a 16% prevalence of elevated ALAT (>38 IU/L for women and >50 IU/L for men)<sup>15</sup> and a 40% prevalence of elevated CRP (>3.0 mg/L)<sup>16</sup> have been found among newly diagnosed patients with T2D. As well, potentially modifiable predictors of elevated ALAT/CRP have been identified, including low physical activity (ALAT: relative risk (RR) 1.4, 95% CI 1.04 to 1.93; CRP: RR 1.46, 95% CI 1.11 to 1.91).<sup>15 16</sup> Such biomarkers may have an impact on the clinical outcome of diabetes, which future prospective studies using DD2 data will be able to examine.

In another study, patients with incident T2D were followed during their first year postdiagnosis. It was found that 74% were receiving glucose-lowering therapy, with 88% receiving monotherapy, mainly metformin. Factors associated with receiving any glucose-lowering therapy included young age (RR 1.29, 95% CI 1.16 to 1.44), central obesity (RR=1.23, 95% CI 1.04 to 1.44), large weight gain since youth (RR=1.10, 95% CI 1.03 to 1.18), lack of regular physical activity (RR=1.07, 95% CI 1.01 to 1.15), high baseline fasting blood glucose (RR=1.25, 95% CI 1.10 to 1.42) and high comorbidity burden (RR=1.20, 95% CI 1.05 to 1.38).<sup>17</sup>

A publication list is provided at [www.dd2.nu](http://www.dd2.nu). The results of many ongoing long-term prospective studies will be reported in years to come including genotype studies investigating the association between genotypes and pharmacological treatment strategies on relevant endpoints like glycaemic control and albuminuria.

## STRENGTHS AND LIMITATIONS

The DD2 project has established a large population-based cohort of newly diagnosed patients with T2D, with demographic, anthropometric, lifestyle and clinical data. Furthermore, the project maintains a valuable biobank. Use of the unique individual-level CPR identifier makes it possible to avoid multiple registrations and to take advantage of existing data in Danish health and administrative registries in a cost-effective way. These

registries also provide a source of long-term follow-up data. Since much of the data are recorded by health personnel during diagnosis and treatment, and not for research purposes, investigator bias is reduced. In addition, the validity of Danish registry data is high. As an example, reporting of cancer to the DCR is mandatory, and completeness is secured by cross-checking with other registries including DRCD and the Danish Pathology Registry.<sup>11 21</sup> In the DNPR, the positive predictive value of, for example, hospital discharge diagnoses included in the CCI is 94%–100%.<sup>22</sup>

A few limitations of the DD2 cohort must be noted. First, while DD2 and DDDA data are nearly complete for demographic variables and for many clinical variables such as smoking, physical activity, hip–waist ratio and resting heart rate, the proportion of missing data is large for some variables. For example, in the DDDA, BMI is missing for 26% of women. However, waist–hip ratio is available for 100% of the DD2 cohort and constitutes a better predictor of cardiovascular complications than BMI.<sup>23</sup> Second, linkage to the DDDA currently is only possible for 73% of DD2 participants, partly explained by the data delay associated with the DDDA's role as a clinical quality improvement registry. Its mandate is to report on quality of care based on data collected during the previous year (ie, patients need to have prevalent T2D for 1–2 years before they are eligible for quality-of-care assessment). In contrast, the DD2 project focuses on incident T2D and is tasked with collecting data at time of diagnosis.<sup>7</sup> Moreover, while reporting to the DDDA by GPs became mandatory in 2013, all GP reporting discontinued in September 2014 due to conflicting interpretation of legal issues concerning automated data transmission. Third, while it was planned for the DD2 cohort to recruit newly diagnosed T2D patients, approximately 85% already have initiated glucose-lowering treatment at enrolment. This hampers analyses of biomarkers among treatment-naïve patients with T2D. However, the exact start date of glucose-lowering therapy can be ascertained from prescription registries. Fourth, since predominantly patients from outpatient specialist clinics were enrolled in early study years, that is, during 2010–2012, the cohort initially may have contained newly diagnosed patients with T2D with more advanced disease than average. However, the baseline data presented in this paper are similar to baseline data in a recent registry-based cohort study investigating patients with T2D from the Northern Region of Denmark at initiation of their first glucose-lowering therapy,<sup>24</sup> thus reassuring that exposures of interest are represented for Danish patients with T2D in earlier phases of the disease. Finally, a large proportion of patients in the DD2 cohort were enrolled during the last few years, which limits current opportunities for conducting long-term follow-up studies.

In the future, the DD2 cohort will serve as a strong national and international resource for recruiting patients to nested case studies and clinical trials, postmarketing surveillance, large-scale genome studies, intervention

studies, for example, in patients with rare diabetic subtypes, and follow-up studies of diabetes complications.

## COLLABORATION

More information about the DD2 cohort can be found at the DD2 website [www.dd2.nu](http://www.dd2.nu). The DD2 project has a Steering Group with members from GP practices/hospital research units in all regions of Denmark. The Steering Group strongly encourages national and international collaboration. Interested researchers can contact Director Dr Henning Beck-Nielsen at [henning.beck-nielsen@syd.dk](mailto:henning.beck-nielsen@syd.dk).

## Author affiliations

<sup>1</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

<sup>2</sup>Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark

<sup>3</sup>Department of Pharmacology, University of Aarhus, Aarhus, Denmark

<sup>4</sup>Department of Endocrinology, Bispebjerg, University Hospital Copenhagen, Copenhagen, Denmark

<sup>5</sup>Department of Endocrinology, Odense Universitetshospital, Odense, Denmark

<sup>6</sup>Department of Biochemistry, Lillebaelt Hospital, Vejle, Denmark

<sup>7</sup>Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark

<sup>8</sup>Cardiovascular and Metabolic Disease (CVMD) Translational Medicine Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden

<sup>9</sup>Department of Health Research & Policy (Epidemiology), Stanford University, Stanford, California, USA

**Contributors** HB-N, HTS, JSC, JR, AV, SF, IB, JSN and RWT designed the DD2 cohort and raised the funding. IB is in charge of storage and analyses of biological samples. SKN and KB performed all the statistical analyses. DHC and RWT wrote the first draft of this report. All authors critically revised the manuscript and approved the final version.

**Funding** The Danish Centre for Strategic Research in Type 2 Diabetes Project (DD2) is supported by the Danish Agency for Science (grant number 09-067009, 09-075724), the Danish Health and Medicines Authority, the Danish Diabetes Association, Sundhedsstyrelsen and an unrestricted donation from Novo Nordisk A/S. Project partners are listed on the website [www.DD2.nu](http://www.DD2.nu). Furthermore, this work was supported in part by the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation.

**Competing interests** The salary of DHC is paid by the International Diabetic Neuropathy Consortium (IDNC) research programme, which is supported by a Novo Nordisk Foundation Challenge Programme grant (grant number NNF140C0011633). AV started employment at AstraZeneca in March 2016. JSC has served on advisory boards and speaker panels for Novo Nordisk. The remaining authors report no personal conflicts of interest pertaining to this work. Moreover, the Department of Clinical Epidemiology, Aarhus University Hospital, participates in the IDNC research programme and is involved in the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation. The Department of Clinical Epidemiology, Aarhus University Hospital, also receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study.

**Patient consent** Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

**Ethics approval** The DD2 Project was approved by the Regional Committee on Health Research Ethics for Southern Denmark (Record number S-20100082) and the Danish Data Protection Agency (2008-58-0035).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** See Collaboration section.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

1. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, *et al*. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011;364:829–41.
2. Christensen DH, Rungby J, Thomsen RW. Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014. *Clin Epidemiol* 2016;8:381–7.
3. Steffensen C, Thomsen RW, Vaag A, *et al*. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project: rationale and planned nationwide studies of genetic predictors, physical exercise, and individualized pharmacological treatment. *Clin Epidemiol* 2012;4:7–13.
4. Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. *Eur J Epidemiol* 2014;29:541–9.
5. Nielsen JS, Thomsen RW, Steffensen C, *et al*. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system. *Clin Epidemiol* 2012;4:27–36.
6. Christensen H, Nielsen JS, Sørensen KM, *et al*. New national Biobank of The Danish Center for Strategic Research on Type 2 Diabetes (DD2). *Clin Epidemiol* 2012;4:37–42.
7. Thomsen RW, Friborg S, Nielsen JS, *et al*. The Danish centre for strategic research in type 2 diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. *Clin Epidemiol* 2012;4:15–19.
8. Schmidt M, Schmidt SA, Sandegaard JL, *et al*. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;7:449–90.
9. Charlson ME, Pompei P, Ales KL, *et al*. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
10. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, *et al*. Existing data sources for clinical epidemiology: The Danish national database of reimbursed prescriptions. *Clin Epidemiol* 2012;4:303–13.
11. Gjerstorff ML. The Danish cancer registry. *Scand J Public Health* 2011;39:42–5.
12. Helweg-Larsen K. The Danish register of causes of death. *Scand J Public Health* 2011;39:26–9.
13. Andersen JS, Olivarius NF, Krasnik A. The Danish national health service register. *Scand J Public Health* 2011;39:34–7.
14. Lab News 6/2015. Change in Proinsulin C-peptide analysis. Department of Biochemistry, Lillebaelt Hospital, Vejle, Denmark. <http://www.sygehuslillebaelt.dk/wm473198> (accessed Aug 2016).
15. Mor A, Svensson E, Rungby J, *et al*. Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study. *Diabetes Metab Res Rev* 2014;30:707–15.
16. Svensson E, Mor A, Rungby J, *et al*. Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort. *BMC Endocr Disord* 2014;14:74.
17. Mor A, Berencsi K, Svensson E, *et al*. Prescribing practices and clinical predictors of glucose-lowering therapy within the first year in people with newly diagnosed Type 2 diabetes. *Diabet Med* 2015;32:1546–54.
18. Svensson E, Berencsi K, Sander S, *et al*. Association of parental history of type 2 diabetes with age, lifestyle, anthropometric factors, and clinical severity at type 2 diabetes diagnosis: results from the DD2 study. *Diabetes Metab Res Rev* 2016;32:308–15.
19. Steffensen C, Thomsen HH, Dekkers OM, *et al*. Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. *Clin Endocrinol* 2016;85:202–6.
20. Ried-Larsen M, Thomsen RW, Berencsi K, *et al*. Implementation of interval walking training in patients with type 2 diabetes in Denmark: rationale, design, and baseline characteristics. *Clin Epidemiol* 2016;8:201–9.

21. Storm HH, Michelsen EV, Clemmensen IH, *et al.* The Danish Cancer Registry--history, content, quality and use. *Dan Med Bull* 1997;44:535-9.
22. Thygesen SK, Christiansen CF, Christensen S, *et al.* The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. *BMC Med Res Methodol* 2011;11:83.
23. Czernichow S, Kengne AP, Huxley RR, *et al.* Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. *Eur J Cardiovasc Prev Rehabil* 2011;18:312-9.
24. Thomsen RW, Baggesen LM, Svensson E, *et al.* Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study. *Diabetes Obes Metab* 2015;17:771-80.